Brentuximab vedotin, a highly active ADC as a new therapeutic option for CD30+ lymphomas

ISSN： 1865-5041

Source： memo - Magazine of European Medical Oncology, Vol.6, Iss.4, 2013-12, pp. : 275-277

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Therapeutic Immunoconjugates. Which Cytotoxic Payload: Chemotherapeutic Drug (ADC) or Radionuclide (ARC) ?

Current Cancer Therapy Reviews, Vol. 12, Iss. 1, 2016-10 ,pp. : 54-65

Bentham Science Publishers

Access to resources Recommend Favorite

Metformin: a new option in cancer treatment

By Belda-Iniesta Cristóbal

Clinical and Translational Oncology, Vol. 13, Iss. 6, 2011-06 ,pp. : 363-367

Springer Publishing Company

Access to resources Recommend Favorite

Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival

By Sugita Yasuo Takase Yukari Mori Daisuke Tokunaga Osamu Nakashima Akihiko Shigemori Minoru

Journal of Neuro-Oncology, Vol. 82, Iss. 3, 2007-05 ,pp. : 249-256

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of MINE as a front-line therapeutic modality in intermediate- and high-grade non-Hodgkin's lymphomas

By Celik I. Kars A. Guler N. Barista I. Tekuzman G. Ozyilkan O. Hayran M. Firat D.

European Journal of Cancer, Vol. 34, Iss. 5, 1998-04 ,pp. : 759-760

Elsevier

Access to resources Recommend Favorite

"Scrambler therapy": a new option in neuropathic pain treatment?

By Serafini Giuseppe Marineo Giuseppe Sabato Alessandro F.

The Pain Clinic, Vol. 12, Iss. 4, 2000-12 ,pp. : 287-298

Maney Publishing

Access to resources Recommend Favorite